Erasca, Inc.
ERAS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761918
No open-market purchases or sales by Erasca, Inc. insiders were filed in the last 90 days; 256 institutions reported holding it in 13F filings for Q2 2026, worth $5.13B in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Erasca, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- −3 vs. Q2 2023
- Shares held
- 71.3M
- −3.05M (−4.1%) vs. Q2 2023
- Total value
- $140.4M
- −$64.8M (−31.6%) vs. Q2 2023
- New holders
- 9
- 48 more added
- Sold out
- 12
- 29 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ERAS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 256 | $5.13B |
| Q1 2026 | 225 | $4.39B |
| Q4 2025 | 154 | $815.7M |
| Q3 2025 | 141 | $468.5M |
| Q2 2025 | 142 | $277.1M |
| Q1 2025 | 154 | $307.3M |
| Q4 2024 | 146 | $579.5M |
| Q3 2024 | 132 | $633.4M |
| Q2 2024 | 126 | $480.6M |
| Q1 2024 | 108 | $149.7M |
| Q4 2023 | 119 | $147.5M |
| Q3 2023 | 109 | $140.4M |
| Q2 2023 | 112 | $205.2M |
| Q1 2023 | 118 | $234.9M |
| Q4 2022 | 107 | $343.9M |
| Q3 2022 | 88 | $627.9M |
| Q2 2022 | 89 | $428.3M |
| Q1 2022 | 82 | $626.6M |
| Q4 2021 | 63 | $988.0M |
| Q3 2021 | 55 | $919.8M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Erasca, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 1,762,645 | $3.47M | 0.00% | +465,813+35.9% | Added |
| International Biotechnology Trust PLC | 1,926,000 | $3.79M | 1.28% | +500,000+35.1% | Added |
| PFM Health Sciences, LP | 3,930,633 | $7.74M | 0.37% | −866,827−18.1% | Reduced |
| Artal Group S.A. | 4,721,194 | $9.30M | 0.41% | 00.0% | Unchanged |
| Vanguard Group Inc | 5,115,112 | $10.1M | 0.00% | −1,508,119−22.8% | Reduced |
| BlackRock Inc. | 7,027,243 | $13.8M | 0.00% | +110,089+1.6% | Added |
| Armistice Capital, LLC | 8,356,000 | $16.5M | 0.49% | +500,000+6.4% | Added |
| Cormorant Asset Management, LP | 10,813,246 | $21.3M | 1.24% | 00.0% | Unchanged |
| ARCH Venture Management, LLC | 11,055,554 | $21.8M | 14.15% | 00.0% | Unchanged |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −136,201−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −104,137−100.0% | Sold out |
| State of Wisconsin Investment Board | 0 | $0 | 0.00% | −43,053−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −32,507−100.0% | Sold out |
| Oppenheimer & Co Inc | 0 | $0 | 0.00% | −26,287−100.0% | Sold out |
| Erste Asset Management GmbH | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −23,100−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −20,900−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −17,198−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −12,056−100.0% | Sold out |
| Martingale Asset Management L P | 0 | $0 | 0.00% | −11,032−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −1,818−100.0% | Sold out |